This document discusses the implementation of the WHO European Region's Health 2020 policy framework from 2012-2014. It outlines two strategic objectives and four common policy priorities for health. It describes moving from developing the policy to taking action by helping countries update their national health policies and improve public health capacities. The document also discusses promoting the framework, building implementation capacity, supporting country cooperation, and exploring new partnerships to advance the goals of Health 2020 across Europe.
Item 12 - Whole of Government Gender Strategy - Elisabeth WHITE (Sweden)OECD Governance
Presentation given at the OECD Gender Budgeting Experts Meeting, Vienna, Austria. 18-19 June 2018
For more information see http://www.oecd.org/gov/budgeting/gender-budgeting-experts-meeting-2018.htm
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Item 12 - Whole of Government Gender Strategy - Elisabeth WHITE (Sweden)OECD Governance
Presentation given at the OECD Gender Budgeting Experts Meeting, Vienna, Austria. 18-19 June 2018
For more information see http://www.oecd.org/gov/budgeting/gender-budgeting-experts-meeting-2018.htm
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presentation delivered by Mr Imre Holl, Director, Planning Resource Coordination and Performance Monitoring, WHO, at the 67th session of the WHO Regional Committee for Europe
presented by Zsuzsanna Jakab, WHO Regional Director for Europe on 18 November 2014 at Ministerial Meeting in Skopje, The former Yugoslav Republic of Macedonia
Home Care Compliance Program Presentation (sound embed)wedas4jc
I custom designed this PowerPoint template for our agency and I put together the presentation. Since Compliance can be a dull subject, the Compliance Manager wanted to me to create a “fun feel” presentation. You will notice that in the music clip on one of the slides and some of the graphics. Please view in slide show mode to get the best feel of the presentation and to hear the sound.
SEEDS of health and health equity in the context of sustainable human develop...UNDP Eurasia
This presentation shows the work conducted as part of a project initiated by the UNDP Regional Bureau for Europe and the Commonwealth of Independent States in 2013, systematically analyzing whether, how, and in which ways UNDP’s development projects address social, economic and environmental determinants of health and health equity.
The project was implemented in collaboration with the UCL Institute of Health Equity in London, UK. It outlines the study aims, context, opportunities, partnerships, methodologies used, key findings and most importantly recommendations for the future.
Health literacy in the WHO European Region, Dr Bente Mikkelsen, Director, Noncommunicable Diseases and Promoting Health through the Life-course / Kristina Mauer-Stender, Acting Director, Information, Evidence, Research and innovation (WHO Regional Office for Europe)
Presentation delivered by Dr Dr Ala Alwan, WHO Regional Director for the Eastern Mediterranean at the 62nd Session of the WHO Regional Committee for the Eastern Mediterranean
Program expenditure classification - Cristina CLASARA, PhilippinesOECD Governance
This presentation was made by Cristina CLASARA, Philippines, at the 13th Annual Meeting of OECD-Asian Senior Budget Officials held in Bangkok, Thailand, on 14-15 December 2017
Regional strategy to improve access to medicines and vaccines in the Eastern Mediterranean Region (2020‒2030), including lessons from the COVID-19 pandemic
Presented at the 66th session of the WHO Regional Committee for Europe by Dr Claudia Stein, Director,
Information, Evidence, Research and Innovation, WHO/Europe
Presented by Agis D. Tsouros, Director, Division Policy and Governance for Health and well-being, WHO/Europe at the 64th session of the WHO Regional Committee for Europe, on 16 September 2014.
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, on 15 September 2015, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation delivered by Mr Imre Holl, Director, Planning Resource Coordination and Performance Monitoring, WHO, at the 67th session of the WHO Regional Committee for Europe
presented by Zsuzsanna Jakab, WHO Regional Director for Europe on 18 November 2014 at Ministerial Meeting in Skopje, The former Yugoslav Republic of Macedonia
Home Care Compliance Program Presentation (sound embed)wedas4jc
I custom designed this PowerPoint template for our agency and I put together the presentation. Since Compliance can be a dull subject, the Compliance Manager wanted to me to create a “fun feel” presentation. You will notice that in the music clip on one of the slides and some of the graphics. Please view in slide show mode to get the best feel of the presentation and to hear the sound.
SEEDS of health and health equity in the context of sustainable human develop...UNDP Eurasia
This presentation shows the work conducted as part of a project initiated by the UNDP Regional Bureau for Europe and the Commonwealth of Independent States in 2013, systematically analyzing whether, how, and in which ways UNDP’s development projects address social, economic and environmental determinants of health and health equity.
The project was implemented in collaboration with the UCL Institute of Health Equity in London, UK. It outlines the study aims, context, opportunities, partnerships, methodologies used, key findings and most importantly recommendations for the future.
Health literacy in the WHO European Region, Dr Bente Mikkelsen, Director, Noncommunicable Diseases and Promoting Health through the Life-course / Kristina Mauer-Stender, Acting Director, Information, Evidence, Research and innovation (WHO Regional Office for Europe)
Presentation delivered by Dr Dr Ala Alwan, WHO Regional Director for the Eastern Mediterranean at the 62nd Session of the WHO Regional Committee for the Eastern Mediterranean
Program expenditure classification - Cristina CLASARA, PhilippinesOECD Governance
This presentation was made by Cristina CLASARA, Philippines, at the 13th Annual Meeting of OECD-Asian Senior Budget Officials held in Bangkok, Thailand, on 14-15 December 2017
Regional strategy to improve access to medicines and vaccines in the Eastern Mediterranean Region (2020‒2030), including lessons from the COVID-19 pandemic
Presented at the 66th session of the WHO Regional Committee for Europe by Dr Claudia Stein, Director,
Information, Evidence, Research and Innovation, WHO/Europe
Presented by Agis D. Tsouros, Director, Division Policy and Governance for Health and well-being, WHO/Europe at the 64th session of the WHO Regional Committee for Europe, on 16 September 2014.
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, on 15 September 2015, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation delivered by Claudia Stein, Director, Division of Information, Evidence, Research and Innovation, on 15 September 2015, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation by WHO/Europe Regional Director Zszsanna Jakab at the WHO European Ministerial Conference on Nutrition and Noncommunicable Diseases in the Context of Health 2020, in Vienna, Austria, on 4 July 2013
Presented by Claudia Stein, Director, Division of Information, Evidence, Research and Innovation, WHO/Europe, at the 64th session of the WHO Regional Committee for Europe.
Presentation by Romina Boarini, Director of the WISE Centre at the OECD, during the launch of the report How to Make Societies Thrive? Coordinating Approaches to Promote Well-being and Mental Health, on 17 October 2023
Leen Meulenbergs, Executive Manager, Strategic Partnerships, WHO Representative to the European Union, WHO Regional Office for Europe, 67th session of the WHO Regional Committee
Presentation – The Issue-based Coalition on Health and Well-being
12 May 2017, Geneva, Switzerland
By Dr Zsuzsanna Jakab, WHO Regional Director for Europe
Sixth meeting of the European Advisory Committee on Health Research (EACHR) - presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe - 15 April 2015, Copenhagen, Denmark
Presentation by Dr Zsuzsanna Jakab,WHO Regional Director for Europe, at the Third High-level Meeting of the Small Countries Initiative, in Monaco, on 11–12 October 2016
Non-Communicable Diseases: Malaysia in Global Public HealthFeisul Mustapha
Paper presented at a CME Session, held in conjunction with the NIH Research Week 2014, 26 November 2014 at the Institute for Health Management, Bangsar
Similar to Health 2020 implementation, 2012–2014 (20)
Reported measles cases for the period November 2020—October 2021 (data as of 02 December 2021).A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the WHO European Region
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
3. : a new health policy framework for Europe
Health 2020:
2 strategic objectives
+
4 common policy
priorities for
health
Moving from words to action
New values and new knowledge
translated into evidence-informed policy
interventions
Going upstream to address root causes,
to improve health in a more equitable
and sustainable way
How? Helping countries to update their
national health policies, strategies and
plans and to improve their public health
capacities and services
4. Making Health 2020
known across the Region
: moving from words to action
Promoting evidence to
accelerate action
Health 2020 in the work
of the Regional Office
Building capacity
for implementation
Optimizing support
for countries
Health 2020 developments
across Europe
6. in the work of the Regional Office
Taking the
Health 2020
vision forward
in countries
Biennial
collaborative
agreements
(BCAs) for
2014–2015
Country
cooperation
strategies (CCSs)
in Europe
7. : building implementation capacity
• Two senior posts (dealing
with national health policies
and governance for health)
established in the Regional
Office
• Briefings and training for
senior health-policy
consultants on
implementing Health 2020
• Health 2020
implementation package
Introducing Health 2020
to different stakeholders
across sectors
Applying the Health
2020 lens to country
situation analysis
Implementing whole-of-government
and whole-of-
society approaches
Addressing the social
determinants of health,
equity, gender and
human rights
Developing Health-2020-
based national and
subnational health policies,
strategies and plans
Strengthening public
health capacities and
services
Strengthening
monitoring and
evaluation
Operationalizing new
concepts and evidence
Integrated approaches
to implementing the
four priority policy areas
of Health 2020
8. : exploring and supporting new partnerships
• Close collaboration between the WHO
Regional Office for Europe and Member
States to engage with partners
• Effective cooperation between WHO
and other United Nations agencies, the
European Union and its institutions, the
Organisation for Economic Co-operation
and Development, global
health partnerships, subregional
networks and nongovernmental
organizations
10. • We seek to build momentum, with a movement involving many
partners across the European Region to make this happen
• The success of Health 2020’s implementation will be judged
against its fundamental goals.
Editor's Notes
Two years ago together we made a promise to the peoples of our Region to accelerate our efforts for improving health and well-being and reducing inequalities. Endorsing Health 2020 meant a commitment to strong values such as the right to health, equity and universal coverage and a will to put health high on the social and political agenda of your governments. Health is a political choice. Understanding health and well-being as a shared goal of whole governments and whole of societies is key to a 21st century approach to health and it is at the heart of Health 2020. We have come a long way to understand better the significance of the social determinants of health and we have come a long way to understand that the health sector alone cannot address the systemic and multi-faceted risks of todays public health challenges. Moreover we have understood better that health can make a significant contribution to the achievement of the goals of many other sectors.
Taking forward the Health 2020 vision requires strong leadership, mobilizing many actors and creating adequate capacities for implermentation at all levels As Regional Director, I have made it my first priority to see that Health 2020 is implemented to its full promise.
Health 2020 is indeed fully consistent with all these themes. I should like to re-emphasize that health and well-being are essential for sustainable economic and social development and of vital concern to the lives of every person, family and community. Enabling people to exercise control over their health and its determinants builds communities and improves their health.. Health 2020 has given us the framework to connect better and more strategically with development agendas and also the United Nations Development Assistance Frameworks (UNDAFs) as well as other UN reform processes.
Its implementation has become the guiding force for all of the work of the WHO Regional Office. It has given us the strategic entry points to not only seriously address inequities and health in all policies but also to renew commitment on strengthening public health with emphasis on population and life-course based approaches to prevention and health promotion. Vitally Health 2020 has made a strong moral and economic case for “going upstream” to address root causes. Reaching out to different sectors and levels of government with clear arguments and robust evidence is essential. Today’s health policy must be multi-faceted and multisectoral, with the active involvement of all levels of government and other actors at international, national and local levels. I have created new resources and reinforced our expertise to allow us to have the necessary capacity to support you in your efforts to work across sectors.
Since the adoption of Health 2020 by the Regional Committee in 2012 significant and promising developments implementing the Health 2020 vision can be already shown across the Region. This is evidence that you have taken this challenge seriously. Most importantly I have been encouraged by your openness and willingness to use the Health 2020 political leverage to tackle challenging aspects of your health systems and health improvement strategies. For instance striving for universal coverage, protecting vulnerable populations, investing in prevention, tackling comprehensively NCDs or giving your children a healthy start in life. In my presentation I should like to give you an overview of how we have adjusted and oriented the work of the whole European Office to implementing Health 2020. In this context a large focus of our work with countries has been on updating their national health policies, strategies and plans to be aligned and coherent with Health 2020. Today throughout the Region many of you have already embarked on processes of establishing inter-ministerial mechanisms for health. I am very impressed by these developments and I am particularly interested in ensuring that such efforts are sustainable and contribute to change and innovation.
We have vigorously focused on capacity building activities and types of support to countries that can deliver maximum impact. These cover 6 main areas of work: making Health 2020 known across the Region and building commitment; promoting the evidence and recommendations of our studies to accelerate action; aligning the work of the Regional Office with every aspect of Health 2020; building capacity for implementation; optimizing outcomes through better coordinated and integrated delivery in countries; and responding to country requests for support. The working document on the Health 2020 implementation in the past two years provides a detail account of progress and activities in each of these six areas. We have also produced a brochure with an quick overview of the scope of the work under each of the six headings.
We do not work alone. As I said earlier Health 2020 must actively engage a wide diversity of stakeholders in working together to improve health and well-being. Since its endorsement I have been invited to many countries for national launches and debates on Health 2020, and met with prime ministers and presidents to discuss health from a whole-of-government and whole-of-society perspective. I am most grateful for these conversations. In addition, several recently appointed ministers of health have been invited to the Regional Office in Copenhagen for official visits, during which the Health 2020 policy framework was presented and considered from the perspective of each country. Health 2020 has also been promoted at a variety of international health conferences and public health fora across Europe. The sub-regional launches represent unique platforms for policy dialogues on Health 2020 approaches and the recommendations of our three major studies on the social determinants, governance for health and on the economics of prevention as well as sharing and learning from real experiences. I am grateful to the UK, Finland, Montenegro and Uzbekistan for their support to organise such launches. Next year I should like to initiate a series of meetings with different sectors and begin to build a more robust basis for collaboration.
An important component of the integration of Health 2020 into the work of the Office has been biennial collaborative agreements (BCAs) for the 2014–2015 biennium, which have a new structure that facilitates understanding how a country intends to take the Health 2020 vision forward in the national context and how the Regional Office can support those efforts, both at the strategic level and with specific technical approaches. Work is also under way to roll out a Country Cooperation Strategy (CCS) in the European Region within the Health 2020 policy framework. We have developed road-maps identifying key policy and strategic entry points in the implementation of Health 2020 in all BCA countries.
Resources are essential for implementing Health 2020. In order to strengthen the overall support to Health 2020 implementation, a number of strategic and pragmatic decisions have been made, including a call for health policy experts to be seconded to the Regional Office to implement Health 2020. This was successful and two senior posts, on national health policies and governance for health, have been established recently in the Regional Office. A first round of briefings and training for senior health policy consultants on implementation of Health 2020 took place in early 2014 and a second round will be held shortly.
A resource “package” of tools and services for Health 2020 implementation has been produced, designed for people and institutions in political and technical roles in countries, including ministers and ministries of health, health associations and agencies, WHO country offices, other government and sector actors and WHO networks. The package combines tools, services and written materials to support evidence-informed policy development, institutional strengthening and stakeholder engagement. It will be made available on the web and regularly updated. I am giving special priority to producing sectoral briefs to allow us to have a more meaningful and focused dialogue with other sectors. We will circulate an example such brief on Education and we would welcome your feedback.
Key to the success of Health 2020 will be close collaboration of Member States and WHO and reaching out to engage with international partners. The Regional Office has worked to establish and maintain effective collaboration with many partners, for example United Nations agencies, the European Union and its institutions, the OECD, global health partnerships such as the GAVI Alliance and The Global Fund to Fight AIDS, Tuberculosis and Malaria, sub-regional networks and nongovernmental organizations. The Office has also collaborated with a number of civil society actors, including nongovernmental organizations, philanthropic foundations and academia.
Many Member States are now taking up the Health 2020 challenge. The paper: Implementing Health 20220: 2012-2014 gives many examples of progress in countries and illustrations of good practices. A number of national health policies have or are being aligned with Health 2020, and this process with continue in the 2014-2015 biennium. There have also been a number of national reviews of health policies, strategies and laws through the Health 2020 perspective. With the support of the Regional Office, numerous Member States have also conducted assessments of governance for health, applying the Health 2020 lens and increasing their capacity for implementing whole of government and health in all policy approaches. Countries have begun identifying national indicators and targets to monitor progress in the implementation of Health 2020.
I greatly welcome these developments. In this short introductory presentation I have avoided giving country-by-country examples, but may I mention two particular significant developments? I am greatly heartened to see that many Member States are working to implement the Health 2020 vision by indeed strengthening public health services and capacities. And in the countries of the South-eastern Europe Health Network (SEEHN) the Health 2020 policy framework was been used as a foundation for incorporating health into the SEE 2020 growth strategy, with support from the Regional Office. In parallel, the Network is developing a SEEHN health strategy based on Health 2020 goals. This is a very exciting development, bringing health and well-being alongside sustainable development in an integrated way. I should also like to make reference to the small countries Health 2020 initiative that has lead to an exciting new platform of cand support involving 8 of our Member States.
Health 2020 aims to further improve the health and well-being of the European regional populations, in a more equitable way that hitherto. The policy framework provides both the evidence and the evidence-based recommendations to make these goals reality. We need to continue promoting and encouraging the political and social commitment of governments, civil society, transnational bodies and academic institutions to translate this into reality. We seek a momentum, a movement in fact, involving many partners across the European Region to make this happen. We have the knowledge and technology to improve health and well-being yet further in the European Region, and we can do this more equitably. Health 2020 shows us the way, and its success will be judged against these fundamental goals. I should like to see an acceleration of our efforts today and in the months to come to make the Health 2020 vision a reality in every corner of our Region.